Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer

@article{Tsunoda2004PhaseIS,
  title={Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer},
  author={Toshiyuki Tsunoda and Tomonobu Koizumi and Muneharu Hayasaka and Kazuya Hirai and Shigeru Koyama and Yasuki Takabayashi and Keisaku Fujimoto and Keishi Kubo},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={54},
  pages={173-177}
}
To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). A group of 38 patients with advanced or metastatic NSCLC who had not received prior treatment and who were aged under 75 years were enrolled. The patients received intravenous infusions of docetaxel (25 mg/m2, days 1, 8, 15) and cisplatin (80 mg/m2, day 1), followed by a week of… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

  • JD Hainsworth, HA IIIBurris, EM Thomas, FA Greco
  • J Clin Oncol
  • 1998
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…